Page 443 - ILAE_Lectures_2015

29. ISOJARVI JI, LAATIKAINEN TJ, KNIP M, PAKARINEN AJ, JUNTUNEN KT, MYLLYLA VV (1996)
Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 39, 579-584.

30. VAINIONPAA LK, RATTYA J, KNIP M et al (1999) Valproate-induced hyperandrogenism during pubertal
maturation in girls with epilepsy. Ann Neurol 45, 444-450.

31. BETTS T, YARROW H, DUTTON N et al (2003) A study of anticonvulsant medication on ovarian function
in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of
women without epilepsy. Seizure 12, 323-329.

32. MURIALDO G, GALIMBERTI CA, MAGRI F et al (1997) Menstrual cycle and ovary alterations in women
with epilepsy on antiepileptic therapy. J Endocrinol Invest 20, 519-526.

33. BAUER J, JARRED A, KLINGMULLER D, ELGER CE (2000) Polycystic ovary syndrome in patients with
focal epilepsy: a study in 93 women. Epilepsy Res 41, 163-167.

34. FERIN M, MORRELL M, XIAO E et al (2003) Endocrine and metabolic responses to long-term monotherapy
with the antiepileptic drug valproate in the normally cycling rhesus monkey. J Clin Endocrinol Metab 88,
2908-2915.

35. MORRELL MJ, HAYES FJ, SLUSS PM et al (2008) Hyperandrogenism, ovulatory dysfunction, and
polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 64, 200-211.

36. ISOJARVI JI, RATTYA J, MYLLYLA VV et al (1998) Valproate, lamotrigine, and insulin-mediated risks
in women with epilepsy. Ann Neurol 43, 446-451.

37. MIKKONEN K, VAINIONPAA LK, PAKARINEN AJ et al (2004) Long-term reproductive endocrine health
in young women with epilepsy during puberty. Neurology 62(3), 445-450.

38. COULAM BB, ANNEGERS JF (1979) Do anticonvulsants reduce the efficacy of oral contraceptives?
Epilepsia 20, 519-526.

39. ROSENFELD WE, DOOSE DR, WALKER SA et al (1997) Effects of topiramate on the pharmacokinetics
of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 38,
317-323.

40. BARUZZI A, ALBANI R, RIVA R (1994) Oxcarbazepine: pharmacokinetic interactions and their clinical
relevance. Epilepsia 35 (suppl 3), S14-S19.

41. SIDHU J, BULSARA S, JOB S et al (2004) A bidirectional pharmacokinetic interaction study of lamotrigine
and the combined oral contraceptive pill in healthy subjects. Epilepsia 45 (suppl 7), 330.

42. www.fsrh.org/pdfs/CEUStatementADC0110.pdf
43. www.fsrh.org/pdfs/CEUstatementUpdateNewerAntiepilepticAntiretroviralDrugs.pdf
44. HAUKKAMAA M (1986) Contraception by Norplant subdermal capsules is not reliable in epileptic patients

on anticonvulsant therapy. Contraception 33, 559-565.
45. SABERS A, BUCHOLT JM, ULDALL P, HANSEN EL (2001) Lamotrigine plasma levels reduced by oral

contraceptives. Epilepsy Res 47, 151-154.
46. Scottish Obstetric Guidelines and Audit Project (1997) The management of pregnancy in women with

epilepsy. SPC & RLI Publications, No. 5. UPDATE.
47. BELL GS, NASHEF L, KENDALL S et al (2002) Information recalled by women taking anti-epileptic drugs

for epilepsy: a questionnaire study. Epilepsy Res 52, 139-146.
48. CAMPBELL E, DEVENNEY E, MORROW J et al (2013) Recurrence risk of congenital malformations in

infants exposed to antiepileptic drugs in utero. Epilepsia 54(1), 165-171.
49. VADJA F, O’BRIEN T, LANDER CM, GRAHAM J, ROTEN A, EADIE MJ (2013) Teratogenesis in

repeated pregnancies in antiepileptic drug treated women. Epilepsia 54(1), 181-186.
50. SHORVON S (1995) The classical genetics of the epilepsies. In: Epilepsy, 2nd Edition (Eds A Hopkins, S

Shorvon and G Cascino), pp.87-92. Chapman & Hall, London.
51. ROSA FW (1991) Spina bifida in infants of women treated with carbamazepine during pregnancy. N Eng J

Med 324, 674-677.
52. OMTZIGT JG, LOS FJ, GROBBEE DE et al (1992) The risk of spina bifida aperta after first-trimester

exposure to valproate in a prenatal cohort. Neurology 42 (suppl 5), 119-125.
53. LINDHOUT D, OMTZIGT JGC, CORNEL MC (1992) Spectrum of neural-tube defects in 34 infants

prenatally exposed to antiepileptic drugs. Neurology 42 (suppl 5), 111-118.
54. MEDICAL RESEARCH COUNCIL RESEARCH GROUP (MRC) VITAMIN STUDY RESEARCH

GROUP (1991) Prevention of neural-tube defects: results of the Medical research council vitamin study.
Lancet 338, 131-137.
55. CZEIZEL AE, DUDAS I (1992) Prevention of the first occurrence of neural-tube defects by periconceptual
vitamin supplementation. N Engl J Med 327, 1832-1835.
56. ROSENBERG IH (1992) Folic acid and neural-tube defects – time for action? N Engl J Med 327, 1875-1876.
57. VAN ALLEN MI, KALOUSEK DK, CHERNOFF GF et al (1993) Evidence for multi-site closure of the
neural tube in humans. Am J Med Genet 47, 723-743.
58. CRAIG J, MORRISON P, MORROW J et al (1999) Failure of periconceptual folic acid to prevent a neural
tube defect in the offspring of a mother taking sodium valproate. Seizure 8, 253-254.
59. HERNANDEZ-DIAZ S, WERLER MM, WALKER AM, MITCHELL AA (2000) Folic acid antagonists
during pregnancy and the risk of birth defects. N Engl J Med 343, 1608-1614.
60. MORROW JI, HUNT SJ, RUSSELL AJ, et al (2008) Folic acid use and congenital malformations in offspring
of women with epilepsy. A prospective study from the UK Epilepsy and Pregnancy Register. J Neurol
Neurosurg Psychiatry 80, 506-511.
61. TOMSON T, BATTINO D, BONIZZONI E et al For the EURAP Study Group (2011) Dose-dependent risk
of malformations with anti-epileptic drugs: an analysis from the EURAP epilepsy and pregnancy registry.
Lancet Neurol 10, 609-617.